Luca Leone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Luca Leone has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Benedetto Galosi
Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Università Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy
4 shared publications Angelo Marronaro
UOC Urologia, Civitanova Marche, Area Vasta 3, ASUR Marche
3 shared publicationsAlessandra Filosa
UOC Urologia Civitanova Marche, AV 3, ASUR Marche
2 shared publicationsEnrico Caraceni
Urology Operative Unit, Civitanova Marche Hospital, Area Vasta 3 Asur Marche, Civitanova Marche, Italy
2 shared publications- Enrico Caraceni
UOC Urologia, Civitanova Marche, Area Vasta 3, ASUR Marche
2 shared publications - Giulia Sbrollini
Department of Clinical Sciences and Dentistry, Urology Clinic, Az. Ospedaliera Polytechnic University of Marche, Ancona
2 shared publications
Latest Publications
- Open Access
- 1 November 2021
- Published by BMJ in International Journal of Gynecological Cancer
- Vol. 31 (Suppl 4) , A118.2-A118
EPV225/#623 Safety of a new closed co2 peritoneal recirculation system (PRS) hyperthermic intraperioneal chemotherapy (HIPEC) after interval debulking surgery (IDS) in advanced ovarian cancer (AOC) patients
Objectives The avaliability of new devices aimed at improving fluid distribution with a CO2 Peritoneal Recirculation System (PRS-1.0 Combat) may be useful to further improve the clinical benefit recently showed by hypertermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) in advanced ovarian cancer (AOC) patients. This study aimed at assessing the feasibility and perioperative outcomes of the CO2 PRS HIPEC after IDS. Methods Over the study period 24 patients were prospectively enrolled. Patients underwent 3 neoadjuvant cycles of carboplatin AUC5 + paclitaxel 175 mg/m2 and IDS with absent residual disease. Sodium thiosulfate (9 g/m2) was administered before CO2 PRS HIPEC with cisplatin (75 mg/m2, temperature 42°C, for 60 minutes). Results Almost one third of patients (37,5%) underwent ultraradical surgery with 12.5% bowel resections. Median blood loss was 500 (100–1200) mL and mean operative time 407.5 minutes. Median (range) intensive care unit stay and time-to-discharge were 0 (0–10) and 6 (4–17) days, respectively. We registered 3/24 (12.5%) early serious adverse events including one acute respiratory failure and two acute kidney injuries (only one of these retained a mild chronic renal failure); one patient was readmitted within 30 days after discharge because of a dehiscence of the vaginal vault. No late adverse events were reported. Median time-to-chemotherapy was 33 days (range 22- 51). Conclusions The CO2 PRS may improve the safety profile of HIPEC in the setting of IDS for AOC patients probably because of the more tailored drug distribution.
- 1 November 2021
- Published by BMJ in International Journal of Gynecological Cancer
- Vol. 31 (Suppl 4) , A118.2-A118
Open AccessEPV225/#623 Safety of a new closed co2 peritoneal recirculation system (PRS) hyperthermic intraperioneal chemotherapy (HIPEC) after interval debulking surgery (IDS) in advanced ovarian cancer (AOC) patients
Objectives The avaliability of new devices aimed at improving fluid distribution with a CO2 Peritoneal Recirculation System (PRS-1.0 Combat) may be useful to further improve the clinical benefit recently showed by hypertermic intraperitoneal chemotherapy (HIPEC) after interval debulking surgery (IDS) in advanced ovarian cancer (AOC) patients. This study aimed at assessing the feasibility and perioperative outcomes of the CO2 PRS HIPEC after IDS. Methods Over the study period 24 patients were prospectively enrolled. Patients underwent 3 neoadjuvant cycles of carboplatin AUC5 + paclitaxel 175 mg/m2 and IDS with absent residual disease. Sodium thiosulfate (9 g/m2) was administered before CO2 PRS HIPEC with cisplatin (75 mg/m2, temperature 42°C, for 60 minutes). Results Almost one third of patients (37,5%) underwent ultraradical surgery with 12.5% bowel resections. Median blood loss was 500 (100–1200) mL and mean operative time 407.5 minutes. Median (range) intensive care unit stay and time-to-discharge were 0 (0–10) and 6 (4–17) days, respectively. We registered 3/24 (12.5%) early serious adverse events including one acute respiratory failure and two acute kidney injuries (only one of these retained a mild chronic renal failure); one patient was readmitted within 30 days after discharge because of a dehiscence of the vaginal vault. No late adverse events were reported. Median time-to-chemotherapy was 33 days (range 22- 51). Conclusions The CO2 PRS may improve the safety profile of HIPEC in the setting of IDS for AOC patients probably because of the more tailored drug distribution.
- 30 March 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (5) , 789-793
Uretero-iliac artery fistula: a challenge diagnosis for a life-threatening condition: monocentric experience and review of the literature
Uretero-iliac artery fistulae (UIAF) are the consequence of chronic inflammatory events that create a fibrous and poorly vascularized uretero-vascular adhesion. They often occur in patients with a history of surgery, pelvic radiotherapy, and chronic ureteral stenting. The presentation is usually massive gross hematuria with acute anemia unto to hemorrhagic shock, representing a life-threatening condition. High mortality rate is reported (7–23%).
- 30 March 2019
- Published by Springer Nature in International Urology and Nephrology
- Vol. 51 (5) , 789-793
Uretero-iliac artery fistula: a challenge diagnosis for a life-threatening condition: monocentric experience and review of the literature
Uretero-iliac artery fistulae (UIAF) are the consequence of chronic inflammatory events that create a fibrous and poorly vascularized uretero-vascular adhesion. They often occur in patients with a history of surgery, pelvic radiotherapy, and chronic ureteral stenting. The presentation is usually massive gross hematuria with acute anemia unto to hemorrhagic shock, representing a life-threatening condition. High mortality rate is reported (7–23%).
- Open Access
- 30 December 2016
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 88 (4) , 330-332
Rare presentation of a testicular angiofibroma treated with testis sparing surgery
Introduction: Testicular benign tumors are very rare (< 5%). Testicular Angiofibroma (AF) is one of those, however the gold standard of treatment and follow-up is still unclear. Case report: A 47 years-old man with only one functioning testis was referred to our clinic for a palpable right testicular mass and atrophic contralateral testis. Patient underwent testis-sparing surgery with inguinal approach and intraoperative frozen sections examination with diagnosis of AF. Final histology confirmed AF. Post-operative follow-up was uneventful. Clinical and ultrasonographic follow-up was negative after 8 months. Conclusion: We report a conservative surgery in a patient with AF of the solitary testis. AF is a benign para-testicular fibrous neoplasm that could be misinterpreted as malignant tumor and treated with orchiectomy. Testis-sparing surgery is recommended in this case with intraoperative pathological examination. The excision of the mass is enough but in front of a possible recurrence a long follow-up is advisable.
- 30 December 2016
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 88 (4) , 330-332
Open AccessRare presentation of a testicular angiofibroma treated with testis sparing surgery
Introduction: Testicular benign tumors are very rare (< 5%). Testicular Angiofibroma (AF) is one of those, however the gold standard of treatment and follow-up is still unclear. Case report: A 47 years-old man with only one functioning testis was referred to our clinic for a palpable right testicular mass and atrophic contralateral testis. Patient underwent testis-sparing surgery with inguinal approach and intraoperative frozen sections examination with diagnosis of AF. Final histology confirmed AF. Post-operative follow-up was uneventful. Clinical and ultrasonographic follow-up was negative after 8 months. Conclusion: We report a conservative surgery in a patient with AF of the solitary testis. AF is a benign para-testicular fibrous neoplasm that could be misinterpreted as malignant tumor and treated with orchiectomy. Testis-sparing surgery is recommended in this case with intraoperative pathological examination. The excision of the mass is enough but in front of a possible recurrence a long follow-up is advisable.
- Open Access
- 30 December 2016
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 88 (4) , 320-324
Testicular sparing surgery in small testis masses: A multinstitutional experience
Introduction: The incidence of benign testicular tumors is increasing in particular in small lesion incidentally found at scrotal ultrasonography. Primary aim of this study was to perform radical surgery in malignant tumor. Secondary aim was to verify the efficacy of the diagnostic-therapeutic pathway recently adopted in management of small masses with testis sparing surgery in benign lesions. Materials and methods: In this multicenter study, we reviewed all patients with single testis lesion less than 15 mm at ultrasound as main diameter. We applied the diagnostic-therapeutic pathway described by Sbrollini et al. (Arch Ital Urol Androl 2014; 86:397) which comprises: 1) testicular tumor markers, 2) repeated scrotal ultrasound at the tertiary center, 3) surgical exploration with inguinal approach, intraoperative ultrasound, and intraoperative pathological examination. Definitive histology was reviewed by a dedicated uro-pathologist. Results: Twenty-eight patients completed this clinical flowchart. The mean lesion size was 9.3 mm (range 2.5-15). Testicular tumor markers were normal except in a case. Intraoperative ultrasound was necessary in 8/28 cases. We treated 11/28 (39.3%) with immediate radical orchiectomy and 17/28 (60.7%) with testis-sparing surgery. Definitive pathological results were: malignant tumor in 6 cases (seminoma), benign tumor in 10 cases (5 Leydig tumors, 2 Sertoli tumors, 1 epidermoid cyst, 1 adenomatoid tumor, 1 angiofibroma), benign disease in 11 (8 inflammation with haemorragic infiltration, 2 tubular atrophy, 1 fibrosis), and normal parenchyma in 1 case. We observed a good concordance between frozen section examination and definitive histology. Any malignant tumor was treated conservatively. Any delayed orchiectomy was necessary based on definitive histology. Conclusions: The incidence of benign lesions in 60% of small testis lesions with normal tumor markers makes orchiectomy an overtreatment. Testicular sparing surgery of single testicular nodules below 15 mm is a safe option, but requires a standardized pathway in diagnosis. Our pathway has shown good reliability and security profile to be applied in a multicenter management for small scrotal masses. Our study has shown the reliability of the diagnostic-therapeutic pathway in the management of single testicular masses. The higher incidence of benign lesions in 60% of patients makes often orchiectomy an overtreatment.
- 30 December 2016
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 88 (4) , 320-324
Open AccessTesticular sparing surgery in small testis masses: A multinstitutional experience
Introduction: The incidence of benign testicular tumors is increasing in particular in small lesion incidentally found at scrotal ultrasonography. Primary aim of this study was to perform radical surgery in malignant tumor. Secondary aim was to verify the efficacy of the diagnostic-therapeutic pathway recently adopted in management of small masses with testis sparing surgery in benign lesions. Materials and methods: In this multicenter study, we reviewed all patients with single testis lesion less than 15 mm at ultrasound as main diameter. We applied the diagnostic-therapeutic pathway described by Sbrollini et al. (Arch Ital Urol Androl 2014; 86:397) which comprises: 1) testicular tumor markers, 2) repeated scrotal ultrasound at the tertiary center, 3) surgical exploration with inguinal approach, intraoperative ultrasound, and intraoperative pathological examination. Definitive histology was reviewed by a dedicated uro-pathologist. Results: Twenty-eight patients completed this clinical flowchart. The mean lesion size was 9.3 mm (range 2.5-15). Testicular tumor markers were normal except in a case. Intraoperative ultrasound was necessary in 8/28 cases. We treated 11/28 (39.3%) with immediate radical orchiectomy and 17/28 (60.7%) with testis-sparing surgery. Definitive pathological results were: malignant tumor in 6 cases (seminoma), benign tumor in 10 cases (5 Leydig tumors, 2 Sertoli tumors, 1 epidermoid cyst, 1 adenomatoid tumor, 1 angiofibroma), benign disease in 11 (8 inflammation with haemorragic infiltration, 2 tubular atrophy, 1 fibrosis), and normal parenchyma in 1 case. We observed a good concordance between frozen section examination and definitive histology. Any malignant tumor was treated conservatively. Any delayed orchiectomy was necessary based on definitive histology. Conclusions: The incidence of benign lesions in 60% of small testis lesions with normal tumor markers makes orchiectomy an overtreatment. Testicular sparing surgery of single testicular nodules below 15 mm is a safe option, but requires a standardized pathway in diagnosis. Our pathway has shown good reliability and security profile to be applied in a multicenter management for small scrotal masses. Our study has shown the reliability of the diagnostic-therapeutic pathway in the management of single testicular masses. The higher incidence of benign lesions in 60% of patients makes often orchiectomy an overtreatment.
- Open Access
- 27 January 2016
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2016, 1-4
Salvage Procedure in Case of Urethrocavernous Fistula after Revision Surgery for Malfunctioning Three-Piece Penile Prosthesis
Urethrocavernous fistula is a rare complication of penile prosthesis. Literature lacks any materials regarding this complication’s treatment. We report our experience with a 66-year-old man who developed urethrocavernous fistula after penile prosthesis implant. Our technique involves the careful closure of urethral and corpus cavernosum defects with application of TachoSil above the sutures. After the salvage procedure, no recurrence of fistula occurred and patient was able to have sexual intercourse. We believe that our technique may be successfully used in case of urethrocavernous fistula after penile prosthesis implant. Urethrocavernous fistula is a rare complication of penile prosthesis. Literature lacks any materials regarding this complication’s treatment. We report our experience with a 66-year-old man who developed urethrocavernous fistula after penile prosthesis implant. Our technique involves the careful closure of urethral and corpus cavernosum defects with application of TachoSil above the sutures. After the salvage procedure, no recurrence of fistula occurred and patient was able to have sexual intercourse. We believe that our technique may be successfully used in case of urethrocavernous fistula after penile prosthesis implant.
- 27 January 2016
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2016, 1-4
Open AccessSalvage Procedure in Case of Urethrocavernous Fistula after Revision Surgery for Malfunctioning Three-Piece Penile Prosthesis
Urethrocavernous fistula is a rare complication of penile prosthesis. Literature lacks any materials regarding this complication’s treatment. We report our experience with a 66-year-old man who developed urethrocavernous fistula after penile prosthesis implant. Our technique involves the careful closure of urethral and corpus cavernosum defects with application of TachoSil above the sutures. After the salvage procedure, no recurrence of fistula occurred and patient was able to have sexual intercourse. We believe that our technique may be successfully used in case of urethrocavernous fistula after penile prosthesis implant. Urethrocavernous fistula is a rare complication of penile prosthesis. Literature lacks any materials regarding this complication’s treatment. We report our experience with a 66-year-old man who developed urethrocavernous fistula after penile prosthesis implant. Our technique involves the careful closure of urethral and corpus cavernosum defects with application of TachoSil above the sutures. After the salvage procedure, no recurrence of fistula occurred and patient was able to have sexual intercourse. We believe that our technique may be successfully used in case of urethrocavernous fistula after penile prosthesis implant.
- Open Access
- 30 December 2014
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 86 (4) , 332-335
Biopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy
The incidence of prostate cancer (PCA) was evaluated in 155 patients with isolated Atypical Small Acinar Proliferation (ASAP) found on initial prostate biopsy, after a medium-term follow-up (40 months) with at least one re-biopsy. Clinical and histological data were analysed. Cancer was detected in 81 of 155 (52.3%). The cancer detection rate was 71.6%, 91.3%, 97.5%, 100% at the 1st re-biopsy, 2nd, 3rd, and 4th rebiopsy respectively. At the uni- and multivariate analyses, prostate volume (≤ 30 cc), transition zone volume (≤ 10 cc), small core length at the initial biopsy (≤ 10 mm) and few number of cores at initial biopsy (≤ 8) are predictive of cancer. Furthermore, tumour characteristics on the whole surgical specimens was assessed in 30 men: 13 of 30 (43 %) had clinically relevant cancer (volume > 0.5 ml or/and Gleason score ≥ 7, or pT3). Most of relevant cancers were detected in the distal apex, anterior gland and midline. These anatomical sites could be under-sampled at the initial biopsy using the transrectal approach. Our data suggest that follow-up biopsy is recommended in all cases of isolated ASAP detected after biopsy using endfire transrectal probe. The re-biopsy strategy should increase the number of cores (or a saturation biopsy), focusing on area of ASAP in the initial biopsy, but also including the under-sampled areas (anterior gland, distal apex and midline) to detect clinically relevant cancers.
- 30 December 2014
- Published by PAGEPress Publications in Archivio Italiano di Urologia e Andrologia
- Vol. 86 (4) , 332-335
Open AccessBiopsy follow-up in patients with isolated atypical small acinar proliferation (ASAP) in prostate biopsy
The incidence of prostate cancer (PCA) was evaluated in 155 patients with isolated Atypical Small Acinar Proliferation (ASAP) found on initial prostate biopsy, after a medium-term follow-up (40 months) with at least one re-biopsy. Clinical and histological data were analysed. Cancer was detected in 81 of 155 (52.3%). The cancer detection rate was 71.6%, 91.3%, 97.5%, 100% at the 1st re-biopsy, 2nd, 3rd, and 4th rebiopsy respectively. At the uni- and multivariate analyses, prostate volume (≤ 30 cc), transition zone volume (≤ 10 cc), small core length at the initial biopsy (≤ 10 mm) and few number of cores at initial biopsy (≤ 8) are predictive of cancer. Furthermore, tumour characteristics on the whole surgical specimens was assessed in 30 men: 13 of 30 (43 %) had clinically relevant cancer (volume > 0.5 ml or/and Gleason score ≥ 7, or pT3). Most of relevant cancers were detected in the distal apex, anterior gland and midline. These anatomical sites could be under-sampled at the initial biopsy using the transrectal approach. Our data suggest that follow-up biopsy is recommended in all cases of isolated ASAP detected after biopsy using endfire transrectal probe. The re-biopsy strategy should increase the number of cores (or a saturation biopsy), focusing on area of ASAP in the initial biopsy, but also including the under-sampled areas (anterior gland, distal apex and midline) to detect clinically relevant cancers.